RARITAN, NJ--(Marketwired - Apr 28, 2016) - Ortho Clinical Diagnostics (Ortho), a global leader of in vitro diagnostics, today announced that ORTHO™ Sera, a fully automated solution for extended antigen phenotyping, is now available on the ORTHO VISION® Analyzer. ORTHO™ Sera expands the testing menu on the ORTHO VISION®, allowing virtually all testing to be done on one platform, driving greater value and efficiency for customers and delivering results in a maximum of 20 minutes. It will be commercially available in Europe and Japan.
ORTHO™ Sera extended phenotype testing covers more than 99 percent of the most commonly tested blood group antigens, providing support for patients with unexpected antibodies. With end-to-end full automation on the ORTHO VISION® Analyzer platform, ORTHO™ Sera minimizes the potential for human error, which can improve safety and provides consistent, reliable results. ORTHO™ Sera has been developed to use ORTHO BioVue® System Column Agglutination Technology, eliminating the need to purchase additional cassettes.
"With the launch of ORTHO™ Sera for the ORTHO VISION® Analyzer, laboratory professionals can improve workflow and ease-of-use through fully automated extended antigen typing," said Robert Yates, chief operating officer, Ortho Clinical Diagnostics. "This expansion of our comprehensive ORTHO VISION® menu helps laboratories streamline operations and resources due to fewer training requirements, less manual interaction and by utilizing the same cassettes that technicians already use with the instrument."
ORTHO™ Sera enables customized, flexible profile testing through an antisera additive approach. This allows extended phenotyping to be personalized according to patient needs, which reduces waste and enhances efficiency. Decreased hands-on manipulation of tests helps to eliminate time consuming non-value added activities and potential for error.
"Having an integrated portfolio of products with standardized operating procedures is increasingly important for transfusion medicine laboratories," said Heidi Casaletto, head of transfusion medicine at Ortho Clinical Diagnostics. "As pressure mounts to produce results on a shorter timeline and with fewer resources, our complete automated laboratory solution will give results that technicians can be confident in while reducing the potential impact to patient safety."
The 13 ORTHO™ Sera reagents available on the ORTHO VISION® Analyzer platform include Anti-Fya, Anti-Fyb, Anti-Jka, Anti-Jkb, Anti-S, Anti-s, Anti-K, Anti-D (IAT), Anti-D (DVI), Anti-P1, Anti-Lea, Anti-Leb and Anti-M. ORTHO™ Sera manual testing was previously available on ORTHO® Workstation.
About Ortho Clinical Diagnostics
Ortho Clinical Diagnostics is a global leader of in vitro diagnostics serving the global clinical laboratory and immunohematology communities. Across hospitals, hospital networks, blood banks, and labs in more than 120 countries, Ortho's high-quality products and services enable healthcare professionals to make better-informed treatment decisions. For the immunohematology community, Ortho's blood typing products help ensure every patient receives blood that is safe, the right type and the right unit. Ortho brings sophisticated testing technologies, automation, information management, and interpretation tools to clinical laboratories around the world to help them run more efficiently, effectively and improve patient care. Ortho's purpose is to improve and save lives with diagnostics and it does that by reimagining what's possible. This is what has defined Ortho for more than 75 years, and it's what drives Ortho forward. For more information, visit www.orthoclinicaldiagnostics.com.
ORTHO VISION®, ORTHO VISION® Analyzer, and ORTHO™ Sera are trademarks of Ortho Clinical Diagnostics.
© Ortho Clinical Diagnostics 2016
Contact Information:
Press Contact:
Renee Giello
Ortho Clinical Diagnostics
908-704-3678